Active ingredient
Semaglutide: FDA Status, Uses, Safety and Cost
Single receptor target (GLP-1)
What Semaglutide is
Semaglutide is a GLP-1 receptor agonist — a prescription medication that mimics the glucagon-like peptide-1 hormone. It is the active ingredient in three FDA-approved brand products: Wegovy (approved for chronic weight management and cardiovascular risk reduction), Ozempic (approved for type 2 diabetes), and Rybelsus (an oral tablet approved for type 2 diabetes). There is no FDA-approved generic semaglutide.
Key facts
| Generic (active ingredient) | Semaglutide |
|---|---|
| Brand names | Wegovy, Ozempic, Rybelsus |
| Drug class | GLP-1 receptor agonist |
| Manufacturer | Novo Nordisk |
| FDA status | FDA ApprovedApproved for chronic weight management |
| Administration | Subcutaneous injection (Wegovy, Ozempic) or oral tablet (Rybelsus) |
| Frequency | Once weekly (injectable); once daily (oral) |
| Approval date | First semaglutide approval: December 2017 (Ozempic). Weight-management approval: June 2021 (Wegovy). |
| Prescription required | Yes |
| Official label | Prescribing information (DailyMed) |
What Semaglutide is approved for
- Chronic weight management (as Wegovy) in adults and pediatric patients aged 12 and older, as an adjunct to a reduced-calorie diet and increased physical activity
- Reduction of major adverse cardiovascular event risk (as Wegovy) in adults with established cardiovascular disease and either obesity or overweight
- Type 2 diabetes (as Ozempic, injectable; and Rybelsus, oral) — a different indication from weight management
How Semaglutide works
GLP-1 receptor agonists activate receptors for the naturally occurring hormone GLP-1. Per official labeling, semaglutide lowers body weight primarily through reduced calorie intake — it slows gastric emptying and acts on areas of the brain involved in appetite regulation, increasing feelings of fullness.
- 1
Medication binds
A GLP-1 receptor agonist activates the receptor for the natural GLP-1 hormone.
- 2
Signals are sent
Appetite-regulating areas of the brain are affected, increasing fullness.
- 3
Stomach slows
Gastric emptying slows, so food stays in the stomach longer.
- 4
Intake falls
Per FDA labeling, weight reduction happens mainly through eating fewer calories.
Administration
Semaglutide is given by subcutaneous injection (wegovy, ozempic) or oral tablet (rybelsus), once weekly (injectable); once daily (oral).
We do not publish dosing guidance
Dose selection, titration schedules, and what to do about a missed dose are individual clinical decisions. Follow the instructions from your prescriber and the official prescribing information — never a website.
Important safety information
Boxed Warning — the FDA’s most serious warning
Risk of thyroid C-cell tumors: caused thyroid C-cell tumors in rodents at clinically relevant exposures; it is unknown whether this occurs in humans. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Summarized from the product’s FDA prescribing information. Read the full label, linked in Sources below.
Contraindications (who should not take it)
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known serious hypersensitivity to semaglutide or product components
Summarized from the FDA prescribing information. This is not the complete list — see the full label.
Common adverse reactions from official labeling
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Headache
- Fatigue
- Dyspepsia (indigestion)
- Dizziness
The most common adverse reactions listed in the product’s FDA prescribing information. Frequency and full adverse-reaction data are in the label.
Brand and generic relationships
Semaglutide is the active ingredient in the following FDA-approved brand products.
Cost and access
- Semaglutide products are available only by prescription from a licensed clinician.
- There is no FDA-approved generic semaglutide. Products marketed as "generic semaglutide" are not FDA-approved drugs.
- Novo Nordisk operates savings and access programs for eligible patients through NovoCare; terms change frequently — check the manufacturer site for current details.
- The FDA has warned about unapproved compounded and counterfeit semaglutide products sold online.
Why we don't publish a price
List prices, savings-card amounts, and self-pay offers change frequently and vary by pharmacy, plan, and location. Any figure we printed would be wrong for many readers and stale within weeks. See our cost guide for how to get an accurate number for your own situation.
Insurance considerations
- Coverage differs sharply by indication: many plans that cover Ozempic for type 2 diabetes do not cover Wegovy for weight management.
- Medicare Part D is prohibited by statute from covering drugs used for weight loss, but per 2024 CMS guidance may cover Wegovy for its cardiovascular risk-reduction indication in patients who qualify.
More detail: how insurance coverage works for weight-loss medication.
Comparisons
Frequently asked questions
- Is semaglutide FDA approved for weight loss?
- Yes — as the brand Wegovy, semaglutide is FDA approved for chronic weight management in adults and adolescents 12 and older who meet the label criteria. Ozempic and Rybelsus contain the same active ingredient but are approved for type 2 diabetes, not weight management.
- Is there a generic semaglutide?
- No. As of our last review there is no FDA-approved generic semaglutide. Compounded semaglutide sold online is not an FDA-approved product and the FDA has issued warnings about such products.
- What is the difference between Wegovy and Ozempic?
- Both contain semaglutide, but they are approved for different uses and come in different dose strengths: Wegovy is approved for chronic weight management and cardiovascular risk reduction, while Ozempic is approved for type 2 diabetes. See our full Ozempic vs. Wegovy comparison.
Related guides
Sources
- Semaglutide prescribing information (DailyMed, NIH) — DailyMed/NIH. Link last verified August 12, 2026.
- FDA: Medications containing semaglutide — FDA. Link last verified August 12, 2026.
- Drugs@FDA database — FDA. Link last verified August 12, 2026.
Not medical advice. WeightLossDrugsGuide is an independent educational publisher. We are not a pharmacy, a medical provider, or a telehealth clinic, and we do not provide personalized medical recommendations or dosing guidance. Information here summarizes official FDA labeling and other primary sources and may not reflect the most recent changes. Always talk with a licensed clinician about your own situation, and read the full prescribing information for any medication.